US groups seek Supreme Court ruling in Myriad gene patent case, again
This article was originally published in Clinica
Executive Summary
The American Civil Liberties Union and the Public Patent Foundation has asked the US Supreme Court to again overrule a federal court's 16 August decision and invalidate patents held by Myriad Genetics on the BRCA1 and BRCA2 breast and ovarian cancer genes.